Immunome (IMNM) Cash & Equivalents (2019 - 2026)

Immunome (IMNM) has 8 years of Cash & Equivalents data on file, last reported at $582.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 126.19% year-over-year to $582.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582.7 million (up 126.19% YoY) and the FY2025 annual result came in at $653.5 million, up 355.86% from the prior year.
• Cash & Equivalents retreated to $582.7 million in Q1 2026, from $653.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $653.5 million in Q4 2025 to a low of $20.3 million in Q4 2022.
• A 5-year average of $178.9 million and a median of $143.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 58.72% — and 2024, when it surged 507.16%.
• Tracing IMNM's Cash & Equivalents over 5 years: stood at $20.3 million in 2022, then surged by 385.55% to $98.7 million in 2023, then jumped by 45.27% to $143.4 million in 2024, then jumped by 355.86% to $653.5 million in 2025, then decreased by 10.83% to $582.7 million in 2026.
• The last three Cash & Equivalents figures came in at $582.7 million (Q1 2026), $653.5 million (Q4 2025), and $272.6 million (Q3 2025), per Business Quant data.